Preventing lymphocyte migration may mean keeping ahead of multiple sclerosis progression

Abstract

Relapsing-remitting disease (RRRS) has been present from the beginning in approximately 85% of patients with multiple sclerosis. According to observational data, up to 36% of patients with RRRS - despite disease-modifying treatment - will develop into a secondary progressive form of the disease (SPRS) on average within 9 years

Keywords

• Multiple sclerosis
• lymphocyte
• siponimod
• progression